Iceland· IS-EU/1/07/423/001 & 003
Vectibix
A panitumumab product containing panitumumabum inn, registered in Iceland by Amgen Europe B.V.*. The same ATC class is registered in 13 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Panitumumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FE02 (panitumumab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Panitumumab · ATC L01FE02
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Panitumumabum INN
- Manufacturer
- Amgen Europe B.V.*
- Country
- Iceland (IS)
- ATC code
- L01FE02
- ATC class
- Panitumumab
- Defined daily dose
- 30 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean4831045 ml x1 hglISK 76716
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
27 interactions on record for panitumumab.
Graded by severity as the source publishes them — 14 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Panitumumab · interactions on record
27 records
- 14 severe
- 13 moderate
Most severe, free to view
- AmiodaroneC01BD01severe
- DofetilideC01BD04severe
- DronedaroneC01BD07severe
- IrinotecanL01CE02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Panitumumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumVectibix 20 mg/mlAmgen Europe
- CzechiaVECTIBIXAmgen Europe B.V., Breda
- FinlandVectibixAmgen Europe B.V.
- IrelandVectibix 20 mg/mL concentrate for solution for infusionAmgen Europe B.V.,
- NorwayVectibixAmgen Europe B.V.
- PolandVectibixAmgen Europe B.V.
- SwedenVectibix 20 mg/ml Koncentrat till infusionsvätska, lösningAmgen Europe B.V.
- United StatesVectibixAmgen, Inc
Authorised across Europe · EMA
The same active substance is authorised in 1 EEA country. Names it is sold under:
- Norway · Vectibix
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ece08edd-4e4a-4820-867b-2f8674126a5f GET /v1/drugs/ece08edd-4e4a-4820-867b-2f8674126a5f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Innrennslisþykkni, lausn",
"source": "lyfjastofnun",
"atc_raw": "L01FE02",
"marketed": true,
"strength": "20 mg/ml",
"ma_number": "EU/1/07/423/001 & 003",
"substance": "Panitumumabum INN",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "39475"
}See everything about panitumumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.